Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brock CS, Young H, O’Reilly SM, Matthews J, Osma S, Evans H, Newlands ES and Price P (2000) Early evaluation of tumour metabolic response using [18F]-fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high grade gliomas. Br J Cancer 82: 608–615.
Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturn V and Heiss WD (1993) Correlation of glucose consumption and tumour cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79: 853–858.
Jones T (1996) The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med 23: 211
Maisie (2000) Need article title. Br J Cancer 82: 00–00.
Price P (1997) Is there a future for PET in oncology?. Eur J Nucl Med 24: 587–589.
Price P (2000) PET in diagnostic oncology: A necessary tool today. Eur J Cancer 36: 691–693.
Price P and Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?. Eur J Cancer 31A: 1924–1927.
Saleem A, Aboagye EO and Price P (2000) In vivo monitoring of drugs using radiotracer techniques. Adv Drug Dev Rev 41: 21–39.
Schelling M, Avril N, Näkrig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jännke F, Graett H and Schwaiger M (2000) Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689–1695.
Smith IC, Welch A, Hutcheon A, Mitler I, Payne S, Chilcott P, Waiker S, Whitaker T, Ah-See A, Eremin O, Heys S, Gilbert F and Sharp P (2000) Positron emission tomography using [18F] fluorodeoxy-P-glucose to predict the pathological response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676–1688.
Weber, Ziegler S, Thodman R, Hanauske AK and Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumours using FDG PET. Nucl Med 35: 1773–1782.
Young H, Brock C, Wells, and Price, (1999a) Monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography (PET). Drug Information Journal 33: 237–244.
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammert SMA, Pruim J and Price P (1999b) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 35: 1773–1782.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Price, P. Changes in18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?. Br J Cancer 83, 281–283 (2000). https://doi.org/10.1054/bjoc.2000.1342
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1342